FR2947729B1 - Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale - Google Patents

Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale

Info

Publication number
FR2947729B1
FR2947729B1 FR0954819A FR0954819A FR2947729B1 FR 2947729 B1 FR2947729 B1 FR 2947729B1 FR 0954819 A FR0954819 A FR 0954819A FR 0954819 A FR0954819 A FR 0954819A FR 2947729 B1 FR2947729 B1 FR 2947729B1
Authority
FR
France
Prior art keywords
mucosal
diabetes
treatment
type
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0954819A
Other languages
English (en)
French (fr)
Other versions
FR2947729A1 (fr
Inventor
Philippe Perovitch
Marc Maury
Jean-Pierre Dumonteix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0954819A priority Critical patent/FR2947729B1/fr
Application filed by Individual filed Critical Individual
Priority to US13/383,101 priority patent/US9161910B2/en
Priority to BR112012000596A priority patent/BR112012000596A2/pt
Priority to CN2010800381696A priority patent/CN102481254A/zh
Priority to JP2012519040A priority patent/JP2012532852A/ja
Priority to MX2012000466A priority patent/MX337606B/es
Priority to PCT/FR2010/051426 priority patent/WO2011004117A1/fr
Priority to EP10742210A priority patent/EP2451436A1/fr
Priority to IN977DEN2012 priority patent/IN2012DN00977A/en
Priority to RU2012104639/15A priority patent/RU2543635C2/ru
Publication of FR2947729A1 publication Critical patent/FR2947729A1/fr
Application granted granted Critical
Publication of FR2947729B1 publication Critical patent/FR2947729B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR0954819A 2009-07-10 2009-07-10 Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale Expired - Fee Related FR2947729B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR0954819A FR2947729B1 (fr) 2009-07-10 2009-07-10 Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale
IN977DEN2012 IN2012DN00977A (enExample) 2009-07-10 2010-07-07
CN2010800381696A CN102481254A (zh) 2009-07-10 2010-07-07 用于通过颊透粘膜途径来治疗ii 型糖尿病的餐后高血糖的方法和药物组合物
JP2012519040A JP2012532852A (ja) 2009-07-10 2010-07-07 ２型糖尿病における食後高血糖の経頬粘膜治療の方法、および当該治療に用いられる医薬組成物
MX2012000466A MX337606B (es) 2009-07-10 2010-07-07 Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal.
PCT/FR2010/051426 WO2011004117A1 (fr) 2009-07-10 2010-07-07 Procédé et compositions pharmaceutiques pour le traitement de l'hyper glycémie post-prandiale du diabète de type ii par voie trans-muqueuse buccale
US13/383,101 US9161910B2 (en) 2009-07-10 2010-07-07 Method and pharmaceutical compositions for trans-buccal mucosa treatment of postprandial hyperglycaemia in type II diabetes
BR112012000596A BR112012000596A2 (pt) 2009-07-10 2010-07-07 processo e composições farmacêuticas para o tratamento de hiperglicemia pós-prandial de diabetes tipo ii por via transmucosa bucal
RU2012104639/15A RU2543635C2 (ru) 2009-07-10 2010-07-07 Способ и фармацевтические композиции для лечения постпрандиальной гипергликемии диабета ii типа введением через слизистую ротовой полости
EP10742210A EP2451436A1 (fr) 2009-07-10 2010-07-07 Procédé et compositions pharmaceutiques pour le traitement de l'hyper glycémie post-prandiale du diabète de type ii par voie trans-muqueuse buccale

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0954819A FR2947729B1 (fr) 2009-07-10 2009-07-10 Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale

Publications (2)

Publication Number Publication Date
FR2947729A1 FR2947729A1 (fr) 2011-01-14
FR2947729B1 true FR2947729B1 (fr) 2012-01-20

Family

ID=41571558

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0954819A Expired - Fee Related FR2947729B1 (fr) 2009-07-10 2009-07-10 Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale

Country Status (10)

Country Link
US (1) US9161910B2 (enExample)
EP (1) EP2451436A1 (enExample)
JP (1) JP2012532852A (enExample)
CN (1) CN102481254A (enExample)
BR (1) BR112012000596A2 (enExample)
FR (1) FR2947729B1 (enExample)
IN (1) IN2012DN00977A (enExample)
MX (1) MX337606B (enExample)
RU (1) RU2543635C2 (enExample)
WO (1) WO2011004117A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940116B1 (fr) * 2008-12-22 2012-07-06 Philippe Perovitch Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale
FR3000896B1 (fr) * 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
FR3031668A1 (fr) 2015-01-20 2016-07-22 Philippe Perovitch Dispositif d'administration d'un principe actif par voie per-muqueuse buccale.
FR3053244A1 (fr) 2016-07-01 2018-01-05 Philippe Perovitch Dispositif d'administration d'au moins un principe actif par voie per-muqueuse buccale.
CN107669683B (zh) * 2017-09-30 2020-07-03 杭州华东医药集团新药研究院有限公司 含有西格列汀与二甲双胍的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2071779C1 (ru) * 1993-05-12 1997-01-20 Хабаровский химико-фармацевтический завод Способ получения пантокрина для инъекций
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US7411089B2 (en) * 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
SE528866C2 (sv) * 2005-07-01 2007-02-27 Volvo Lastvagnar Ab Anordning för att kontrollera höjden hos en last eller lastbärare bakom förarhytten hos en lastbil
JP2009508815A (ja) * 2005-08-30 2009-03-05 アボット・ラボラトリーズ ジペプチジルペプチダーゼ−ｉｖ（ｄｐｐ−ｉｖ）の阻害薬としての医薬組成物
DE102006027790A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Typ-2-Diabetes Kombinations-Wafer
CA2659245A1 (en) * 2006-07-28 2008-01-31 Novadel Pharma Inc. Anti-migraine oral spray formulations and methods
FR2906140B1 (fr) 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs

Also Published As

Publication number Publication date
MX337606B (es) 2016-03-10
JP2012532852A (ja) 2012-12-20
IN2012DN00977A (enExample) 2015-04-10
CN102481254A (zh) 2012-05-30
US20120190618A1 (en) 2012-07-26
WO2011004117A1 (fr) 2011-01-13
RU2543635C2 (ru) 2015-03-10
BR112012000596A2 (pt) 2016-02-10
MX2012000466A (es) 2012-04-19
EP2451436A1 (fr) 2012-05-16
US9161910B2 (en) 2015-10-20
FR2947729A1 (fr) 2011-01-14
RU2012104639A (ru) 2013-08-20

Similar Documents

Publication Publication Date Title
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
EP2322221A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER
EP2844346A4 (en) PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
EP2464219A4 (en) MULTI-TRANSGENIC PIGS FOR DIABETES TREATMENT
EP2718318A4 (en) NEW OXYNTOMODULIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADIPOSITAS THEREWITH
EP2552417A4 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF BLADDER HYPERACTIVITY
EP2542255A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE DEGOS SYNDROME
EP2734500A4 (en) SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS
EP2726066A4 (en) DOSE FORMS FOR ORAL ADMINISTRATION AND TREATMENT METHODS THEREWITH
FR2960542B1 (fr) Peptide en tant que medicament, en particulier pour le traitement du cancer
EP2884994A4 (en) COMPOSITION FOR THE TREATMENT OF HYPERLIPIDEMIA WITH AN OXYNTOMODULIN DERIVATIVE
EP2532364A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
FR2948016B1 (fr) Orthese pour le traitement de la rhizarthrose
EP2512240A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TRIGEMINO AUTOMOTIVE ZEPHALGIA, MIGRAINE AND VASCULAR DISEASES
EP2493896A4 (en) PHARMACEUTICAL COMPOSITION WITH CYCLO-METALLED N-HETEROCYCLIC CARBON COMPOUNDS FOR CANCER TREATMENT
EP2470553A4 (en) POLYHYDROYLATED GALLEN ACID FOR THE TREATMENT OF GALLERY DISEASES
EP2666471A4 (en) PHARMACEUTICAL COMPOSITION FOR MILK AND LIVER AND MANUFACTURING METHOD THEREFOR
EP2844279A4 (en) DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS POMPE
EP2323641A4 (en) NYASOL AND ANALOGUE THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR-BETA-MEDIATED ILLNESSES
EP2394648A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
PL2429507T3 (pl) Kompozycja farmaceutyczna wolna od fosforanów do leczenia jaskry
EP2776042A4 (en) ACTIVE COMBINATION THERAPY FOR THE TREATMENT OF SOLID TUMORS
EP1981668A4 (en) METHOD FOR PRODUCING A METAL STRUCTURE FOR SEMI-FINISHED METAL WORKING
EE201300004A (et) Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks
FR2947729B1 (fr) Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

ST Notification of lapse

Effective date: 20210305